The NyokAssist device, from China, had few adverse outcomes by 30 days. More devices—and more trials—are on the way.

Patrick O’Gara speaks with Sean Pinney about the evaluation and treatment of patients with severe tricuspid regurgitation.

The single-arm INVEST-CTO study showed high procedural success with a two-part intervention, but questions remain.

Experts gathered at the TCT MedTech Innovation Forum to discuss successes, failures, barriers, and solutions in healthcare.

Mamas Mamas and Evald Christiansen discuss the 10-year data comparing DES PCI and CABG for LM disease.

A total of 399 patients underwent TEE and were taking their assigned treatment at 60 days follow-up.

HF outcomes at 3 years were improved, but where stem cells fit in future research is the big unknown, says Jay Traverse.

One question, in light of FREEDOM, is how well new DES compare with CABG in patients with diabetes and multivessel disease.

Physicians will remain in the loop, but AI can “turbocharge and augment our abilities,” an emergency medicine physician says.

TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of ...

Changes are afoot to meet higher caseloads amid rising demand, the survey of 6,830 cardiovascular providers suggests.

Having more-thorough workup uncovered an unexpected root cause and changed the treatment course for 76% of patients.